Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-derived Cell-free DNA Does Not Improve the Detection of Acute Kidney Allograft Rejection Beyond Urinary CXCL9 and CXCL10.

Therapeutic drug monitoring·2026
Same author

Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

ElucidatiNg Immunosuppressant pharmacokinetic variabilities by investigating Gut Microbiome modulations After kidney transplantation (ENIGMA): study protocol of a prospective longitudinal trial.

BMJ open·2026
Same author

Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort study.

Journal of geriatric oncology·2026
Same author

The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congress.

Pharmacogenomics·2026
Same author

Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.

Journal of Crohn's & colitis·2026

Related Experiment Video

Updated: Oct 26, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.2K

CYP3A4 Genotyping in Clinical Practice: Ready for Implementation?

Tessa A M Mulder1, Ruben A G van Eerden2, Mirjam de With1,2

  • 1Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, Netherlands.

Frontiers in Genetics
|July 26, 2021
PubMed
Summary

Genetic variations in Cytochrome P450 3A4 (CYP3A4) influence drug metabolism. This review summarizes CYP3A4's pharmacogenetic effects on drug pharmacokinetics, aiding personalized medicine.

Keywords:
CYP3A4CYP3A4∗22cytochrome P450genotype-guided dosinggenotypingpersonalized medicinepharmacogeneticsrs35599367

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.4K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K

Related Experiment Videos

Last Updated: Oct 26, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.2K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.4K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K

Area of Science:

  • Pharmacogenetics
  • Drug Metabolism
  • Enzyme Kinetics

Background:

  • Cytochrome P450 3A4 (CYP3A4) is a key liver enzyme metabolizing approximately 50% of prescribed drugs.
  • Genetic variations in CYP3A4 can impact drug pharmacokinetics, toxicity, and treatment outcomes.
  • Pharmacogenetic studies on CYP3A4 have been limited until the discovery of the intron 6 SNP rs35599367C > T.

Purpose of the Study:

  • To review current knowledge on CYP3A4 pharmacogenetics.
  • To assess the impact of CYP3A4 genetic variations on drug therapy.
  • To guide decisions on CYP3A4 genotype-based dosing for improved drug efficacy.

Main Methods:

  • Literature review of studies investigating CYP3A4 genetic variations and their effects on drug pharmacokinetics.
  • Analysis of data on the CYP3A4 allele (rs35599367C > T) and its prevalence (3-5%).
  • Synthesis of findings related to CYP3A4's influence on specific drug classes.

Main Results:

  • CYP3A4 genetic variations significantly affect the pharmacokinetics of various drugs.
  • Tacrolimus, cyclosporine, and statins are among the most studied drugs influenced by CYP3A4 genotype.
  • The CYP3A4 allele exhibits a functional impact on enzyme activity.

Conclusions:

  • CYP3A4 genotype influences drug pharmacokinetics, suggesting potential for genotype-based dosing.
  • Further research is needed to establish the clinical utility of CYP3A4 genotype-based dosing for toxicity and clinical outcomes.
  • Personalized drug therapy may be enhanced by considering CYP3A4 genetic variations.